Standout Papers

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and... 2016 2026 2019 2022 1.9k
  1. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016)
    Silvia Novello, Fabrice Barlési et al. Annals of Oncology
  2. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018)
    Timothy A. Chan, Mark Yarchoan et al. Annals of Oncology
  3. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2017)
    John B.A.G. Haanen, Franck Carbonnel et al. Annals of Oncology
  4. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer (2017)
    Solange Peters, D. Ross Camidge et al. New England Journal of Medicine
  5. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2018)
    David Planchard, Sanjay Popat et al. Annals of Oncology
  6. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance (2019)
    Filipe Martins, Sofiya Latifyan et al. Nature Reviews Clinical Oncology
  7. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2017)
    Pieter E. Postmus, Keith M. Kerr et al. Annals of Oncology
  8. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2012)
    Solange Peters, Alex A. Adjei et al. Annals of Oncology
  9. Brain metastases (2019)
    Achal S. Achrol, Robert C. Rennert et al. Nature Reviews Disease Primers
  10. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2014)
    Martin Reck, Sanjay Popat et al. Annals of Oncology
  11. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022)
    John B.A.G. Haanen, Michel Obéid et al. Annals of Oncology
  12. Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives (2013)
    Julien Mazières, Solange Peters et al. Journal of Clinical Oncology
  13. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study (2020)
    Charles M. Rudin, Mark M. Awad et al. Journal of Clinical Oncology
  14. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2013)
    Martin Früh, Dirk De Ruysscher et al. Annals of Oncology
  15. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours (2017)
    Émilie Le Rhun, Michael Weller et al. Annals of Oncology
  16. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study (2020)
    Tony Mok, D. Ross Camidge et al. Annals of Oncology
  17. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2013)
    Johan Vansteenkiste, Dirk De Ruysscher et al. Annals of Oncology
  18. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2023)
    Lizza Hendriks, Keith M. Kerr et al. Annals of Oncology
  19. Overcoming therapy resistance in EGFR-mutant lung cancer (2021)
    Antonio Passaro, Pasi A. Jänne et al. Nature Cancer
  20. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study (2019)
    D. Ross Camidge, Rafał Dziadziuszko et al. Journal of Thoracic Oncology
  21. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2015)
    Nicolas Girard, Enrico Ruffini et al. Annals of Oncology
  22. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ (2021)
    Anne‐Marie C. Dingemans, Martin Früh et al. Annals of Oncology
  23. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2015)
    Paul Baas, Dean A. Fennell et al. Annals of Oncology
  24. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2023)
    Lizza Hendriks, Keith M. Kerr et al. Annals of Oncology
  25. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study (2022)
    Melissa L. Johnson, Byoung Chul Cho et al. Journal of Clinical Oncology
  26. A neutrophil response linked to tumor control in immunotherapy (2023)
    Jeremy Gungabeesoon, Nicolas A. Gort-Freitas et al. Cell
  27. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment (2024)
    Antonio Passaro, Maise Al Bakir et al. Cell
  28. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies (2022)
    Antonio Passaro, Julie R. Brahmer et al. Journal of Clinical Oncology
  29. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 (2022)
    Solange Peters, Arnaud Scherpereel et al. Annals of Oncology
  30. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges (2023)
    Giannis Mountzios, Jordi Remón et al. Nature Reviews Clinical Oncology

Immediate Impact

2 by Nobel laureates 6 from Science/Nature 101 standout
Sub-graph 1 of 17

Citing Papers

New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 Standout
21 intermediate papers

Works of Solange Peters being referenced

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2023 Standout
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2023 Standout
and 28 more

Author Peers

Author Last Decade Papers Cites
Solange Peters 18833 17096 4548 5876 421 29.1k
Myung‐Ju Ahn 21786 21982 5021 7271 708 31.1k
Enriqueta Felip 22899 22212 5519 8796 776 32.5k
Keunchil Park 17565 16632 3891 6064 564 26.7k
Joan H. Schiller 19626 18781 4571 9659 342 30.4k
Corey J. Langer 17063 16729 3052 5718 556 27.9k
Suresh S. Ramalingam 15160 14115 4074 8642 584 24.7k
Julie R. Brahmer 28602 18304 4586 7584 349 37.4k
Martin Reck 17003 13355 3125 4386 397 22.2k
Fabrice Barlési 15052 13130 3183 4919 566 21.4k
Mark A. Socinski 15354 14798 2994 4880 516 22.4k

All Works

Loading papers...

Rankless by CCL
2026